DESCRIPTION

• Notes: Biosafety: The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions. Troubleshooting Guide: Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.
• Shiptemp: -80°C (dry ice)
• Warnings: Avoid freeze/thaw cycles
• Category: CAR-T/Lentivirus
• Background: B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF) and is involved in B cell proliferation and maturation. BCMA is preferentially expressed in mature B lymphocytes and the soluble form of BCMA can be found at higher levels in the serum of Multiple Myeloma (MM) patients. BCMA is a highly attractive target antigen for immunotherapy. BCMA, similarly to CD19, is restricted in expression to mature B cells allowing the progenitorʹs population to be spared during treatment and to replenish the patientʹs B cell population. BMCA targeting therapies include bispecific antibodies, antibody-drug conjugates and chimeric antigen receptor (CAR) T cells. To date, the FDA has approved two BCMA CAR-T therapies for the treatment of MM, that resulted in promising outcomes for patients. Further studies will allow a better understanding of the role of BCMA in cancer and fine tune cancer therapy tools.
• Description: The anti-BCMA CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to transduce most mammalian cells, including primary and non-dividing cells. These viruses transduce cells with the ScFv (single-chain variable fragment) that recognizes two BCMA epitopes (clones VHH1 and VHH2), linked to a CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. The lentiviruses also include a puromycin selection marker.
• Formulation: The lentiviruses were produced from HEK293T cells, concentrated and resuspended in DMEM. Virus particles can be packaged in custom formulations by special request, for an additional fee.
• Supplied As: 50 µl of anti-BCMA CAR Lentivirus at a titer ≥3x108 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
• Unspsc Code: 41106621
• Unspsc Name: Virus mediated expression vectors or kits
• Applications: Positive control for anti-BCMA CAR evaluation in immune cells. Transduction optimization studies.
• Product Type: Lentivirus
• Biosafety Level: BSL-2
• Related Products: 79725, 79752, 79753
• Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
• Scientific Category: Cancer Therapy Target